This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

16 Mar 2011

Novo Nordisk Approved for Victoza in China

Novo Nordisk has received marketing authorisation for Victoza in Europe, the US, Canada, Japan and a number of other countries, now including China.

Novo Nordisk announced that the Chinese State Food and Drug Administration (SFDA) has approved Victoza for the treatment of type 2 diabetes.


Victoza is the brand name for liraglutide, the first once-daily human Glucagon- Like Peptide-1 (GLP-1) analogue approved in China, developed for the treatment of type 2 diabetes in adults. Victoza is indicated as an add-on to metformin or sulfonylurea (SU) in people with type 2 diabetes.


"The Chinese approval of Victoza represents an exciting opportunity to further advance therapy in people with type 2 diabetes in China,” says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “Diabetes is a rapidly growing disease

Related News